$11 million of cash left. Burned $3.6 million in Q2. Math question, how many quarters left?

Installed TAEUS system at a fourth clinical evaluation site, in the U.S. Year-to-date, more than 50 TAEUS scans have been performed on study participants, a 25% increase from May 2022, and ENDRA remains on track for at least 200 patients to be scanned by year end. These clinical evaluation sites are being used to generate data to support the commercialization of the TAEUS system, and a subset of the data will be used to support ENDRA's submission of its De Novo request.

Oh brother. 50 scans…

Could be a reason for that…just saying…

We’re back on track…..—..—..—

Does Aurinia have an active trial for this?

https://us5.campaign-archive.com/?e=8156d5d11c&u=52c64784d386bd00ea57ee792&id=698d7db4e6

nferna, spot on…

PE of 10. Able to pass through inflation

I think you mean the Glickster has the umbrella drinks.

Jess still hiding?

That’s our Greggors…

“.but keep telling yourself whatever you want to believe”

Sneaky Pete…

Oh I miss those great Saturday Night Live skits!

Peter is running the ship well:

Net revenue for the quarter more than quadrupled to $28.2M from $6.6M in the prior-year quarter as the company continued to add Lupkynis patients thanks to steady conversion rates and payor coverage.

In 1Q 2021, Aurinia’s (AUPH) net revenue dropped ~8% sequentially to $21.6M as the COVID-19 impact hurt Lupkynis sales.

During 2Q 2022, the company added 409 patient start forms compared to 415 PSFs in the prior-year period.

While gross margin for the period slipped to ~94% from ~95% in 2Q 2021, the company’s net loss fell ~25% YoY to $35.5M even as SG&A expenses climbed ~16% YoY to $51.5M.

At the end of the quarter, Aurinia (AUPH) reported $391.7M of cash, cash equivalents, and restricted cash and investments, indicating a ~16% decline from 2021-end.

For 2022, the company continues to forecast $115M-$135M net revenue from sales of Lupkynis, unchanged from the previous projection.

Fall out from Pelosi visit:

CATL, a Chinese supplier of EV batteries, decided to push back announcing a multibillion-dollar North American plant to supply $TSLA and $F due to tensions raised by House Speaker Nancy Pelosi’s trip to Taiwan, according to people familiar with the matter. Discussion isn't public

CATL, a Chinese supplier of EV batteries, decided to push back announcing a multibillion-dollar North American plant to supply $TSLA and $F due to tensions raised by House Speaker Nancy Pelosi’s trip to Taiwan, according to people familiar with the matter. Discussion isn't public

— Special Situations 🌐 Research Newsletter (Jay) (@SpecialSitsNews) August 2, 2022

They had to do something to lure people in… Just saying…

I wish we had a “thumb up” button for this post…

We got the Tesla model though, Mr. Kobers. Plus, I thought that company has company ending patent issues..?

Dennboy66, RVNC’s share price should reflect that it is getting close to approval after all these years, don’t you think?


Closer to its historical low..

$RVNC Not a chart of a company that should see approval of its lead drug in less than 45 days.. pic.twitter.com/xU9M1VN9ij

— Ryan Carson (@RyanCarson222) July 30, 2022

Agreed. That may be happening. But, results are too close..

Apple’s EV is going to be on the high side of cost:

BOOM

*APPLE TAPS LAMBORGHINI EXECUTIVE TO WORK ON ITS ELECTRIC CAR

— zerohedge (@zerohedge) July 27, 2022

Oh Jess, don’t tell me you own AMRN too?????

Jess, Aurinia, a tiny Canadian biotech, would not be able to twist the arm of a US Federal Agency. Unless Glickman slept with the female Director of the agency.. lol..

https://investors.revance.com/news-releases/news-release-details/revance-present-clinical-data-daxibotulinumtoxina-injection-2022

Yes indeed.

Derk, so you think someone is interested in the Glickster’s prize before the results of the court hearing on the patent? That would be patently impossible…

As long as Jess doesn’t sell, it should hold up..

Looks like they are go after the dosing protocol, meaning you can’t patent whether you take one pill after lunch, and one after dinner. Thought it was fishy when the Peter described it.

VICTORIA, British Columbia and ROCKVILLE, Md.Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today received notice regarding the U.S. Patent Office (USPTO) Patent Trial and Appeal Board (PTAB) decision to institute trial on the Inter Partes review (“IPR”) filed by Sun Pharmaceuticals, directed at U.S. Patent No. 10,286,036. This patent is related to the LUPKYNIS® dosing protocol for lupus nephritis.


“While this decision is disappointing, as we have stated from the start of his process, we will vigorously defend this patent,” said Peter Greenleaf, President and CEO, Aurinia Pharmaceuticals. “This patent already had significant review at the USPTO before being approved as being a valid patent by that office and we are fully prepared to continue legal proceedings to protect our intellectual property.”

R.I.P. the Beavers Brother

https://www.cnn.com/2022/07/26/entertainment/tony-dow-obit/index.html

They are tearing apart the patent in that post. Why did they wait so long?

This is a masterpiece, thank you. Somebody is going to take this out for a song..

Should have been stopped

Aurinia Announces Positive CHMP Opinion for LUPKYNIS® (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe.

Opinion? When is approval expected?

Agreed..

I yield to Dew’s experience. Thanks Dew..

As the CRL was solely due to the manufacturing process and not the biologic review, I think that maybe a distinct possibility.. Sept 8th is in range from here..

PDUFA date being real close @ September 8th, we could be hearing any day now.. Playing “Final Countdown” now by the musical group Europe..

voclosporin - EMEA/H/C/005256
indicated in combination with background immunosuppressive therapies for the treatment of adult patients with class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN).
Scope: Possible oral explanation
Action: Oral explanation to be held on 20 July 2022 at 15:30
List of Outstanding Issues adopted on 19.05.2022. List of Questions adopted on

If only the Glickster was still here…

Not gonna happen Jess. These guys have a business….

JRoon71, this should be a sticky post for those that happen to wander in now.. Well done..